Check all Features, Pros and Contras of Twitter with this Review for Free. Download Safe Twitter App and Install It Now on Android or iOS Devices.
- Blog Archive - Reviewed
Read the latest news and articles
from industry experts.
- Pros & Contras of Twitch
Download and Install the Latest
Version of Twitch
- Blog Archive - Reviewed
Suchergebnisse
Suchergebnisse:
SphingoTec Announces Management Changes. Acute and Critical Care Diagnostics. Discover our product portfolio. Newsletter. Innovative diagnostic solutions for unmet medical needs. Wide adoption. Commercial opportunities.
- Blog
Current applications of precision medicine in intensive care...
- Order
Disclaimer: Sphingotest ® penKid ® and sphingotest ® bio-ADM...
- Products
The microtiter plate is a standard tool in analytical...
- Collaboration
SphingoTec develops and markets innovative biomarkers for...
- Company
SphingoTec develops and markets innovative in vitro...
- Resource Center
About us . SphingoTec GmbH develops innovative biomarkers...
- Blog
SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in...
Die neuesten Tweets von @sphingotec
26. März 2024 · 31. August 2023. Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid. The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms. Read more. 09. May 2023
Managing Director & CEO · Berufserfahrung: SphingoTec · Ausbildung: Universität Potsdam · Standort: Hennigsdorf · 475 Kontakte auf LinkedIn. Sehen Sie sich das Profil von Deborah Bergmann auf LinkedIn, einer professionellen Community mit mehr als 1 Milliarde Mitgliedern, an.
- SphingoTec
- Managing Director & CEO
- 486
- Hennigsdorf, Brandenburg, Deutschland
Hennigsdorf/Berlin, Deutschland, 11 April 2022 – Das Diagnostikunternehmen SphingoTec GmbH (SphingoTec) gibt die Anwendung von zwei Biomarkern zur Steuerung eines neuen Covid-19 Medikamentenkandidats bekannt. Der Medikamentenkandidat wird in einer Studie des UKEs zur Anwendung in mittelschwer- und schwerkranken Patienten und Patientinnen erprobt.